Get the Stockscreener App
4.52
3.91%
0.17
Arbutus Biopharma Corp stock is traded at $4.52, with a volume of 556.78K.
It is up +3.91% in the last 24 hours and up +7.62% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.35
Open:
$4.36
24h Volume:
556.78K
Relative Volume:
0.27
Market Cap:
$891.88M
Revenue:
$14.08M
Net Income/Loss:
$-33.50M
P/E Ratio:
-25.77
EPS:
-0.1754
Net Cash Flow:
$-39.72M
1W Performance:
+7.62%
1M Performance:
+7.62%
6M Performance:
+2.49%
1Y Performance:
+40.37%
1-Day Range:
$4.342
$4.525
1-Week Range:
$4.19
$4.53
52-Week Range:
$3.04
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.515 | 859.29M | 14.08M | -33.50M | -39.72M | -0.1754 |
VRTX
Vertex Pharmaceuticals Inc
|
434.48 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.50 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.36 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.79 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.42 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Posts Profit After Moderna Patent Settlement - MyChesCo
ABUS Stock Price, Quote & Chart | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake - Stock Titan
Arbutus Biopharma Corp Q1 2026 Financial Results and Business Update – Clinical Progress in Hepatitis B Therapies - Minichart
Arbutus Biopharma Corporation 8-K Filing: Company Details, Financial Data, and NASDAQ Listing (May 2026) - Minichart
Is Arbutus Biopharma (ABUS) Overvalued After Q1 2026 Earnings Be - GuruFocus
Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 E - GuruFocus
Arbutus Biopharma Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates - Investing.com
Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary - TradingView
Arbutus: Q1 Earnings Snapshot - 10TV
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit - Stock Titan
Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge - Stock Titan
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - Stock Titan
Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS) - Seeking Alpha
MSN Money - MSN
Arbutus Biopharma Corporation (ABUS) Stock Analysis: Exploring a 20% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
5 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Whitefort lifts Arbutus (ABUS) economic stake to 9.8% - Stock Titan
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran - Insider Monkey
Arbutus Drug Candidate Receives FDA Fast Track Designation - MyChesCo
ABUS (Arbutus Biopharma) Other Liabilities for Banks - GuruFocus
FDA grants Arbutus Biopharma drug fast track designation - Pennsylvania Business Report -
Arbutus (ABUS) Stock: Stability Assessment (Momentum Fading) 2026-04-20Trending Momentum Stocks - newser.com
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability - Insider Monkey
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Whitefort Capital Management, LP Increases Stake in Arbutus Biop - GuruFocus
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Arbutus Biopharma (ABUS) Receives FDA Fast Track Designation for Imdusiran - GuruFocus
Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseHere's Why - MarketBeat
Arbutus Biopharma Corporation Files Form 8-K with SEC – Company Details, Address, and NASDAQ Listing Information 24252675 - Minichart
ABUS Receives Fast Track Designation from FDA for Imdusiran - GuruFocus
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - The Manila Times
[8-K] Arbutus Biopharma Corp Reports Material Event - Stock Titan
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote - Stock Titan
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D - Stock Titan
ABUS Technical Analysis | Trend, Signals & Chart Patterns | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - ChartMill
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Arbutus reports results, announces $2.25B Moderna settlement - MSN
ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):